NICB

Biographical Details:

1998 PhD, University College Cork; 1998-1999 Postdoctoral scientist, University Hospital Bern, Switzerland; 1999-2002 Postdoctoral scientist, St. Vincent's University Hospital, Dublin; 2002-2004 Evaluation manager, Health Research Board, Dublin; April 2004-present Senior research officer, National Institute for Cellular Biotechnology, Dublin City University. Sept 2007 - Programme Leader, Targeted Therapies for Cancer

Research Interests:

Breast cancer; melanoma; targeted therapies; receptor tyrosine kinase inhibitors.

Selected Peer Reviewed Journals

• Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N.. 2012. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.. Breast Cancer Research And Treatment, 136, 3, pp717-727.
• Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. 2012. EGFR and HER2 inhibition in pancreatic cancer. Investigational New Drugs, Epub ahead of print,
• McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ.. 2012. ADAM-17: a novel therapeutic target for triple negative breast cancer. Annals Of Oncology, Epub ahead of print,
• Mooney A, Tiedt R, Maghoub T, O'Donovan N, Crown J, White B, Kenny PT.. 2012. Structure--activity relationship and mode of action of N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters: novel organometallic anticancer compounds.. Journal Of Medicinal Chemistry, 55, 11, pp5455-5466.
• O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J.. 2011. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investigational New Drugs, 25, 9, pp752-759-.
• Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ.. 2011. Src: a potential target for the treatment of triple-negative breast cancer. Annals Of Oncology, 22, 10, pp2234-2240.
• Eustace AJ, Dowling P, Henry M, Doolan P, Meleady P, Clynes M, Crown J, O'Donovan N.. 2011. 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines. Journal Of Proteomics, 74, 4, pp490-501.
• Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N.. 2011. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals Of Oncology, 22, 1
• Mooney A, Corry AJ, Ní Ruairc C, Mahgoub T, O'Sullivan D, O'Donovan N, Crown, J, Varughese S, Draper SM, Rai DK, Kenny PT. 2010. Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents. Dalton Trans. 39, 35, pp8228-8239.
• Collins DM., Crown J., O'Donovan N., Devery A., O'Sullivan F., O'Driscoll L., Clynes M., O'Connor R. 2010. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. 28, 4, pp444-.
• O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. 2010. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 9, 6, pp1489-1502.
• Corkery B, Crown J, Clynes M, O¿Donovan N. 2009. Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer. Annals Of Oncology, 20, 5, pp862-867.
• Corry AJ, O¿Donovan N, Mooney A, O¿Sullivan D, Rai DK, Kenny PTM. 2009. Synthesis, structural characterization, in vitro anti-proliferative effect and cell cycle analysis of N-(ferrocenyl)benzoyl dipeptide esters. Journal Of Organometallic Chemistry, 694, 6, pp880-885.
• Walsh N., O'Donovan N., Kennedy S., Henry M., Meleady P., Clynes M., Dowling P. 2009. Identification of pancreatic cancer invasion-related proteins by proteomic analysis. Proteome Science, 7, 3
• Corkery B, O¿Donovan N, Crown J. 2008. Targeted treatment of advanced and metastatic breast cancer with lapatinib. ONCOTARGETS AND THERAPY. 1, , pp21-34.
• Eustace AJ, Crown J, Clynes M, O'Donovan N.. 2008. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.. Journal Of Translational Medicine, 29, 6, pp53-.
• Walsh N, Dowling P, O'Donovan N, Henry M, Meleady P, Clynes M.. 2008. Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. J Proteomics. Journal Of Proteomics, 71, 5, pp561-571.
• Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N.. 2008. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin,lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.. Bmc Cancer, 16, 8, pp9-.
• O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, Duffy MJ. 2007. Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.. Tumor Biology, 28, 6, pp312-317.
• O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M.. 2006. Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Molecular Cancer, 5, , ppArt 74-.
• Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CGJ, Duffy MJ. 2005. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration. 14, 1, pp235-239.
• Kelly LM, Buggy Y, Hill A, O'Donovan N, Duggan C, McDermott EW, O'Higgins NJ, Young L, Duffy MJ.. 2005. Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumor Biology, 26, 4, pp213-216.
• O'Brien N, O'Donovan N, Ryan B, Hill ADK, McDermott E, O'Higgins N, Duffy MJ. 2005. Mammaglobin A in breast cancer: Existence of multiple molecular forms. International Journal Of Cancer, 114, 4, pp623-627.
• *Brid Ryan, *Norma O'Donovan, Brigid Browne, Caroline O'Shea, John Crown, Arnold D.K. Hill, Enda McDermott, Niall O�Higgins, Michael J. Duffy. *Joint first authors. 2005. Expression of Survivin and its Splice Variants Survivin-2B and Survivin-DEx3 in Breast Cancer. British Journal Of Cancer, 92, 1, pp120-124.
• O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N, Duffy MJ. 2003. Caspase 3 in breast cancer. Clinical Cancer Research, 9, 2, pp738-742.
• O'Donovan N, Fischer A, Abdo EM, Simon F, Peter HJ, Gerber H, Buergi U, Marti U. 2002. Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas. Journal Of Endocrinology, 174, 3, pp517-524.
• O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N, Duffy MJ. 2002. Mammaglobin a: a promising marker for breast cancer. Clinical Chemistry, 48, 8, pp1362-1364.
• Mullis PE, O'Donovan N, Eble A, Marti U, Diem P, Burgi U, and Peter HJ. 2000. Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells. Molecular And Cellular Endocrinology, 166, 2, pp111-119.
• O'Donovan N, Galvin M and Morgan JG. 1999. Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenetics And Cell Genetics, 84, 1-2, pp39-42.

Reviews

• Duffy MJ, O'Donovan N, Crown J. 2011. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treatment Reviews, 37, pp151-159.
• Eustace AJ, Mahgoub T, Tryfonopoulos D, O'Donovan N, Crown J. 2010. Prospects for non-immunological molecular therapeutics in melanoma. J BUON 15, pp9-18.
• Ryan BM., O'Donovan N., Duffy MJ. Survivin. 2009. A new target for anti-cancer therapy. Cancer Treatment Reviews, [Epub ahead of print],
• Browne BC., O'Brien N., Duffy MJ., Crown J., O'Donovan N. 2009. HER-2 signaling and inhibition on breat cancer. Current Cancer Drug Targets, 9, pp419-438.
• Duffy MJ., McKiernan E., O'Donovan N., McGowan PM. 2009. The role of ADAMs in disease pathophysiology. Clinica Chimica Acta, 403, pp31-36.
• Duffy MJ., McKiernan E., O'Donovan N., McGowan PM. 2009. Role of ADAMs in cancer formation and progression. Clinical Cancer Research, 15, pp1140-1144.
• O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L. 2007. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. Expert Opinion On Drug Metabolism And Toxicology, 3, pp805-817.
• O'Donovan N, Crown J. 2007. EGFR and HER-2 antagonists in breast cancer. Anticancer Research, 27, pp1285-1294.
• Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. 2007. Survivin: a promising tumor biomarker. Cancer Letters, 249, pp49-60.

Selected Non-peer Reviewed Journals

• Dr Norma O'Donovan. 2008. Targeted Therapies for Breast Cancer. Medicine Weekly, 16 Jan, pp58-.
• Norma O'Donovan. 2007. Targeted Therapies for Breast Cancer. CancerWise, 6, pp35-39.

• Mahgoub T, Eustace AJ, Collins DM, Clynes M, Crown J, O¿Donovan N., Cyclin dependent kinase 4 as a therapeutic target for metastatic melanoma., European Society of Medical Oncology, 08-OCT-10 - 12-OCT-10, Milan
• V. Dieras, M. J. Kennedy, P. Tresca, M. E. Marty, H. Burris, M. DeSilvio, N. O'Donovan, M. Lau, M. Ridderheim and J. Crown, Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC). , American Society of Clinical Oncology, 04-JUN-10 - 08-JUN-10, Chicago
• Walsh S, Tryfonopoulos D, Quinn C, Flanagan L,Pierce A, McDermott E, Evoy D, O'Donovan N, Crown J and Duffy MJ, C-src: A potential target for the treatment of triple-negative breast cancer, American Society of Clinical Oncology, 04-JUN-10 - 08-JUN-10, Chicago
• Collins DM, O'Donovan N, Dean J, Hogan AE, Ballot J, McDonnell D, O'Meara A, Crown J, Trastuzumab induces antibody-dependent cellular cytotoxicity (ADCC) in her-2 non-amplified (non-amp) breast cancer (BC) cells, American Society of Clinical Oncology, 04-JUN-10 - 08-JUN-10, Chicago
• Eustace AJ, Mahgoub T, Kennedy S, Crown J, Larkin AM, Tryfonopoulos D O¿Driscoll L, Clynes M, O¿Donovan N, Targeting SRC kinase in melanoma cells, American Society of Clinical Oncology, 04-JUN-10 - 08-JUN-10, Chicago
• McDermott M, Browne B, Crown J, O¿Brien N, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, O¿Donovan N., eEF2 in acquired lapatinib resistance in HER2 positive breast cancer cells, American Association for Cancer Research, 17-APR-10 - 21-APR-10, Washington
• Corkery B, Crown J, Roche S, O¿Connor R, Tryfonopoulos D, Clynes M, O¿Donovan N., Constitutive activation of Src kinase as a mechanism of acquired resistance to dasatinib in triple negative breast cancer., San Antonio Breast Cancer Symposium, 09-DEC-09 - 13-DEC-09, San Antonio, Texas
• Qadir Z, Crown J, Jensen MR, Clynes M, Slamon D, O' Donovan N, Combining HSP90 inhibition with standard therapies for HER2 positive breast cancer, San Antonio Breast Cancer Symposium, 09-DEC-09 - 13-DEC-09, San Antonio, Texas
• Tryfonopoulos D, O'Donovan N, Corkery B, Collins D, Clynes M, Crown J, DASATINIB IMPROVES RESPONSE TO CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER CELLS., IMPAKT, 07-MAY-09 - 09-MAY-09, Brussels, Belgium
• Eustace A, Crown J, Clynes M, O`Donovan N., Effects of Src kinase inhibition by dasastinib in melanoma cell lines., 6TH INTERNATIONAL SYMPOSIUM ON TARGETED ANTICANCER THERAPIES , 20-MAR-08 - 22-MAR-08, Bethesda, MD, USA
• Browne B, Crown J, Venkatesan N, Pegram M, Clynes M, Duffy MJ, Slamon DJ, O¿Donovan N., Insulin-like growth factor I receptor inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells., 19th EORTC-NCI-AACR Symposium:Molecular Targets and Cancer Therapeutics , 22-OCT-07 - 26-OCT-07, San Francisco
• O'Donovan N, Mechanisms of HER-2 Resistance, 6th International Symposium on Translational Oncology Research, 11-OCT-07 - 14-OCT-07, Dublin, Ireland
• Corkery B, O¿Donovan N, Clynes M, Crown J., Epidermal growth factor receptor (EGFR) inhibition in triple-negative breast cancer (BrCa)., European Cancer Conference, 23-SEP-07 - 27-SEP-07, Barcelona, Spain, 185 - 185
• Brigid Browne, Norma O¿Donovan, Natarajan Venkatesan, Mark Pegram, Martin Clynes, Michael J Duffy, John Crown, Dennis J Slamon., The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in HER-2 positive breast cancer cells, Irish Association for Cancer Research Annual Meeting, 02-MAR-07 - 03-MAR-07, Cork, Ireland
• Corkery B, O¿Donovan N, Clynes M, and Crown, EGFR Inhibition in Triple-negative Breast Cancer Cell Lines, Irish Association for Cancer Research Annual Meeting, 02-MAR-07 - 03-MAR-07, Cork, Ireland
• O'Donovan N, Clynes M, Crown J., Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines., San Antonio Breast Cancer Symposium, 14-DEC-06 - 17-DEC-06, San Antonio, Texas, USA, S105 - S105
• O'Donovan N, Crown J, EGFR and HER-2 Antagonists in Breast Cancer Therapy, Global mRNA and Protein Expression Analysis: Research applications in cancer and other diseases and in biopharmaceutical production, 07-SEP-06 - 08-SEP-07, Dublin, Ireland, 1374 - 1374
• Browne B, O¿Donovan N, Venkatesan N, Pegram M, Clynes M, Duffy MJ, Crown J, Slamon DJ., The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in breast cancer cells., American Association for Cancer Research Annual Meeting, 01-APR-06 - 05-APR-06, Washington, USA, 288 - 289
• O'Brien NA, Maguire TM, O'Donovan N, Hill A, McDermott E, O'Higgins N, Duffy MJ., Mammaglobin A: A breast specific marker., British Association for Cancer Research Annual Meeting, 30-JUN-02 - 03-JUL-02, Glasgow, Scotland, S37 - S37
• Ryan B, O'Shea C, O'Donovan N, Kennedy S, Crown J, McDermott E, Hill ADK, O'Higgins N, Duffy MJ, Survivin mRNA and protein in breast cancer., British Association for Cancer Research Annual Meeting, 30-JUN-02 - 03-JUL-02, Glasgow, Scotland, S87 - S87
• O'Shea C, O'Donovan, N, Browne, B, Ryan B, Maguire T, Crown J, Hill A, McDermott E, O'Higgins N and Duffy MJ, Expression of survivin mRNA and protein in breast cancer., American Association of Cancer Research, 06-APR-02 - 10-APR-02, San Francisco
• O'Donovan N, Beryt, M, Duffy MJ, Slamon D, and Pegram M, Her-2/neu and apoptosis in breast cancer, American Association of Cancer Research, 06-APR-02 - 10-APR-02, San Francisco
• O'Donovan N, Browne B, Crown J, Hill A, McDermott E, O'Higgins N, and Duffy MJ, Caspase 3 and survivin in breast cancer, Irish Association of Cancer Research, 27-SEP-01 - 28-SEP-01, Cork
• O'Donovan N, Crown J, Hill A, McDermott E, O'Higgins N, and Duffy MJ, Caspase in breast cancer, Irish Association of Cancer Research, 14-APR-00 - 15-APR-00, Galway